Related Experiment Videos
Granulocyte growth factors: achieving a consensus
M Boogaerts1, F Cavalli, H Cortés-Funes
1University Hospital, Leuven, Belgium.
Summary
Granulocyte growth factors are recommended for congenital neutropenia, stem cell mobilization, and bone marrow transplant engraftment. Further trials are needed to define their role in cancer therapy and managing toxicities.
Area of Science:
- Oncology
- Hematology
Background:
- Granulocyte growth factors (G-CSFs) are critical in managing neutropenia and supporting hematologic recovery.
- Evidence supports G-CSF use in specific clinical scenarios, including congenital neutropenia and hematopoietic stem cell transplantation.
Framework:
- A consensus meeting by the European School of Oncology evaluated current evidence for G-CSF applications.
- Key indications include alleviating congenital neutropenia, mobilizing peripheral blood progenitor cells, and supporting engraftment post-bone marrow transplantation.
Implementation:
- G-CSF use is indicated for congenital neutropenia and peripheral blood progenitor cell mobilization for autotransfusion.
- It supports engraftment after bone marrow transplantation, including cases of failed engraftment.
- G-CSF can facilitate ganciclovir therapy in AIDS patients with cytomegalovirus (CMV) infection when foscarnet is not an option.
Implications:
- There is a significant need for controlled clinical trials to explore G-CSF's potential in various indications and improve patient outcomes.
- The role of G-CSFs in dose optimization and intensification for solid tumors requires further definition.
- Extramedullary toxicities remain a potential dose-limiting factor in certain cancer treatment regimens.